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Abstract
Alternative splicing (AS) is an intrinsic regulatory mechanism of all metazoans. Recent findings suggest that 100% of
multiexonic human genes give rise to splice isoforms. AS can be specific to tissue type, environment or developmentally
regulated. Splice variants have also been implicated in various diseases including cancer. Detection of these variants will
enhance our understanding of the complexity of the human genome and provide disease-specific and prognostic
biomarkers. We adopted a proteomics approach to identify exon skip events - the most common form of AS. We
constructed a database harboring the peptide sequences derived from all hypothetical exon skip junctions in the human
genome. Searching tandem mass spectrometry (MS/MS) data against the database allows the detection of exon skip events,
directly at the protein level. Here we describe the application of this approach to human platelets, including the mRNA-
based verification of novel splice isoforms of ITGA2, NPEPPS and FH. This methodology is applicable to all new or existing
MS/MS datasets.
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Introduction
Since the publication of the human genome sequence,
understanding the functional complexity of the genome has
become a primary goal of high-throughput experimental research.
By definition, AS contributes to proteomic complexity but it has
also been suggested that AS is a major driver of phenotypic
complexity, though this role remains unproven [1–3]. By splicing
several combinations of exons into different transcripts, AS
generates, from a single gene, multiple isoforms of a protein with
potentially diverse functions. Not only has AS been invoked as an
explanation for our complexity as a species, detection of splice
isoforms has been associated with the cause and progression of
certain diseases. Alternative splicing is associated with a wide
variety of conditions including bipolar disorder, schizophrenia,
cancer, diabetes, multiple sclerosis, cystic fibrosis and asthma (for a
review see Wang & Cooper [4]). Splice isoforms may be
functionally relevant in disease or may act as biomarkers -
indicators of normal or altered biological processes or pharmaco-
logical response to a therapeutic intervention [5]. Biomarkers such
as disease-specific AS isoforms can serve as indicators of disease
susceptibility as well as diagnostic and prognostic markers.
Alternative splicing occurs in many cell types including platelets -
hemostatic, anucleate cells derived from megakaryocytes. Although
devoid of a nucleus, they retain low levels of mRNA which undergo
translation. They have an intact spliceosome and cellular activation
of platelets induces splicing of pre-mRNAs including IL-1b [6] and
tissue factor (TF) [7]. Platelets are primarily involved in thrombus
formation but their functions also extend to pathophysiological
processes such as host defense, regulation of vascular tone,
inflammation and tumor growth [8]. Splice isoforms in platelets
have been implicated in the variable response to aspirin [9] and as
possible antithrombotic drug targets [10]. Blood-based biomarker
discovery would provide minimally invasive and sensitive detection
of disease-associated molecular changes. Disease biomarkers,
serving as specific diagnostic signatures of phenotype, could
improve drug discovery and facilitate the development of modern,
personalized clinical applications.
To date, efforts to detect AS events have relied primarily on
sequencing mature mRNA species. The bulk of our knowledge
comes from mapping expressed sequence tags (ESTs) to the
genome. However, this approach is hindered by the lack of EST
coverage with few ESTs sequenced for most genes [11] and the
central region of mRNAs inadequately represented. More recently,
exon arrays have been developed to determine genome-wide exon
expression levels. This technology detects differences in expression
across a gene to infer the presence of alternative splicing events, but
cannot determine unambiguously what combination of exons is
present on a single mRNA. The inference of AS is confounded
somewhat by the variable hybridization intensities of neighboring
probe sets within a sample and differential gene expression between
samples. Ultra high-throughput sequencing addresses some of the
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This approach can identify many alternative splice variants if
sufficientsequencereadsarecarriedout[13,14].Aslongersequence
reads become available, it will be possible to identify considerable
structure flanking a given AS event.
The capacity to discover AS events at the mRNA level is very
powerful and mRNAseq has provided evidence for AS occurring
in 100% of multi-exonic human genes [13]. It remains unclear
how many of the splice isoforms identified are sufficiently stable to
result in translation products. Studying the proteome circumvents
this issue - a recent study by Tress and coworkers for example,
demonstrated the presence of translated AS isoforms in Drosophila
melanogaster [15]. The development of new, innovative discovery
approaches based on protein expression will greatly enhance the
existing methodologies.
Mass spectrometry (MS) has emerged as a highly effective
analytical technique capable of detecting vast numbers of peptides
in complex mixtures. This is achieved by mapping spectra
generated from a MS experiment to a database of known or,
more commonly, theoretically derived spectra to infer the peptide
sequence. Exon skip splice isoforms are characterized by the
peptides spanning the exon-exon junction of a novel splicing event.
To detect these peptides, we generate a database containing the
theoretical exon-skip junction peptides across a genome. We then
use standard MS search tools to identify junction peptides that
represent exon skip events in MS/MS spectra by comparison with
this database (Fig. 1). Here, we show that this approach can detect
novel exon skip events in human platelets and verify a number of
these at the mRNA level.
Results
Database design
The strategy we employed to generate the database (which we
call SkipE) is outlined in Figure 1. Transcript and exon data were
extracted from Ensembl v46 [16] for all 22,680 annotated human
protein-coding genes. To create exon skip junctions in silico, a gene
containing multiple transcripts was first reduced to a single ‘full
length transcript’ (Fig. 2a) as described in Materials and Methods.
All non-contiguous junction peptides in a ‘full length transcript’
were created such that the termini are trypsin cleavage sites
(Fig. 2b). It is possible to design a database for other proteolytic
enzymes but trypsin is by far the most commonly employed
proteinase in proteomics experiments. Combinations of exons
yielding junction peptides were constrained by the phase of the
exons in order to keep the sequences within the correct reading
frame. Phase describes the number of nucleotides upstream of an
exon that are used to form a codon so that the length of the exon is
a multiple of three. A previous study by Sorek et al. [17] showed,
using coding sequence information from Genbank, that the
majority of orthologous alternatively spliced exons conserved
between human and mouse did not endure a frame shift.
Furthermore, it is likely that many phase shifting splice events
generate transcripts which are degraded via nonsense-mediated
decay [18]. In order to detect only alternative splice events in
which the correct reading frame is maintained, the phase of both
exons joined by the alternatively spliced junction was calculated
and only those junctions with exons of compatible phase were
entered into the database.
Duplicate entries of the same junction peptide mapping to
different genes were removed to eliminate ambiguity, since the
source of such peptides could not be ascribed to a particular gene.
This procedure yielded 307,030 junction peptides for the human
genome. Previous genome-based studies, such as 6-frame transla-
tion of the genome, result in search spaces that are incompatible
with high-throughput approaches. Genome-based methods that
reduce the search space complexity, provide a powerful means to
identify new protein-coding exons and genes but are not
appropriate for direct mapping of exon skips since these junctions
are derived from non-contiguous sequences [19]. The database we
constructed, subject to the constraints described, generates a
search space appropriate for the high-throughput MS/MS
Figure 1. Workflow for the identification of novel exon skip events. A rectangle represents a program, rhombus represents a program
output, cylinder represents a data source and circle represents a program input.
doi:10.1371/journal.pone.0005001.g001
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composition of the human, mouse and rat databases are provided
(Table S1).
The skipE database is in FASTA format and therefore suitable
for use with any of the major search engines; in this case we
employed SEQUEST [20] combined with PeptideProphet and
ProteinProphet for statistical validation of identifications [21]. We
chose a cutoff score of 0.9, a commonly used cutoff in MS/MS
experiments [22], for both tools. We then determined which
junction-spanning peptides are novel and those which were
previously described by comparing peptide sequences with the
Alternative Splice Transcript Database (ASTD) [23–25] and the
International Protein Index database (IPI) [26] using WU-BLAST
(http://blast.wustl.edu). This also filters out junction peptides
which are identical to sequences within ‘‘canonical’’ isoforms,
whether they occur at exon boundaries or elsewhere.
Identification of platelet proteins and AS peptides
Platelet mass spectra were collected and compared with both
the IPI and SkipE databases to identify peptides. The number of
peptides and proteins identified in each database are shown in
table S2. SEQUEST searching against IPI identified 6,292 unique
peptides representing 1,122 unique proteins in the samples with
a ProteinProphet probability score of P.0.9. Since the SkipE
database harbors peptide rather than protein sequences, Protein-
Prophet is inappropriate. Therefore, spectra identified by
comparison with SkipE were validated using a PeptideProphet
probability cut-off of 0.9 resulting in 1,297 unique protein
identifications. Of these, 359 were represented by more than a
single occurrence of the peptide in the dataset.
The spatial distribution of AS identifications closely mirrors that
of the IPI data with the exception of the releasate (Fig. 3a, b). In
this case, more skips were found in the activated than in the
resting samples for the AS data. Although the activation step was
very brief, this may indicate a tendency towards diversification of
the exported proteome in response to platelet activation.
Functionally, this would be advantageous since these cells must
interact with the milieu and other cell types but cannot mount a
transcriptomic response to stimuli. All identified proteins in both
SkipE and IPI data were mapped to KEGG pathways using
Pathway-Express [27] (Table S3 and S4). In a typical MS/MS
data analysis, protein identifications rely on multiple peptide
identifications for any given protein. Since SkipE harbors isolated
peptide sequences, we decided to focus further experiments on
those AS events for which evidence of cognate gene expression
was also obtained in the IPI analysis. Therefore, we constructed a
list of 89 genes which represents the intersection of the AS and IPI
datasets (Table 1).
Figure 2. Generation and usage of the SkipE database. (A) Generation of representative transcripts. Each box represents an exon and each line
is an intron. i), ii) and iii) represent transcripts from a single gene. iv) shows the full length representative transcript used to generate the junction
peptides. (B) Structure of a junction peptide. The top two boxes represent the translated sequences of two separate, non-adjacent exons. The tryptic
cleavage sites are represented by dashed vertical bars. The C-terminal sequence of the upstream exon from the final tryptic site is spliced to the N-
terminus of the downstream exon and extends to the first tryptic cleavage site of the downstream exon.
doi:10.1371/journal.pone.0005001.g002
Figure 3. Characteristics of the exon skip events detected in human platelets. (A) and (B) describe the distribution of the SkipE and IPI
peptides respectively, across the different subcellular compartments for both resting and activated platelet samples.
doi:10.1371/journal.pone.0005001.g003
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Gene Symbol Ensembl Gene ID Exon ID 1 Exon ID 2 Description
ACLY ENSG00000131473 ENSE00000898911 ENSE00000898879 ATP-citrate synthase
ACOX1 ENSG00000161533 ENSE00001222343 ENSE00001117984 Acyl-coenzyme A oxidase 1,
peroxisomal
ACTN4 ENSG00000130402 ENSE00000895798 ENSE00000895787 Alpha-actinin-4
ALOX12 ENSG00000108839 ENSE00000905333 ENSE00000887238 Arachidonate 12-lipoxygenase, 12S-
type
AMPD2 ENSG00000116337 ENSE00001153152 ENSE00000913099 AMP deaminase 2
AP1B1 ENSG00000100280 ENSE00000652055 ENSE00000652051 AP-1 complex subunit beta-1
APOB ENSG00000084674 ENSE00000932268 ENSE00000718984 Apolipoprotein B-100 precursor
APOL1 ENSG00000100342 ENSE00000935990 ENSE00001369317 Apolipoprotein-L1 precursor
ARHGEF7 ENSG00000102606 ENSE00000686804 ENSE00000686825 Rho guanine nucleotide exchange
factor 7
ARHGEF7 ENSG00000102606 ENSE00001236980 ENSE00000686833 Rho guanine nucleotide exchange
factor 7
ATIC ENSG00000138363 ENSE00001363573 ENSE00001146950 Bifunctional purine biosynthesis
protein PURH
ATP5C1 ENSG00000165629 ENSE00001481323 ENSE00001094820 ATP synthase gamma chain,
mitochondrial precursor
C2 ENSG00000204364 ENSE00001467298 ENSE00001467293 Complement C2 precursor
C21orf33 ENSG00000160221 ENSE00001506662 ENSE00001506660 ES1 protein homolog, mitochondrial
precursor
C3 ENSG00000125730 ENSE00001053527 ENSE00000858107 Complement C3 precursor
C3 ENSG00000125730 ENSE00001053551 ENSE00000858104 Complement C3 precursor
CCT5 ENSG00000150753 ENSE00001082664 ENSE00001082663 T-complex protein 1 subunit epsilon
CD109 ENSG00000156535 ENSE00001144336 ENSE00001144250 CD109 antigen precursor
CD109 ENSG00000156535 ENSE00001144243 ENSE00001084417 CD109 antigen precursor
CLTC ENSG00000141367 ENSE00000948100 ENSE00000948105 Clathrin heavy chain 1
CLTCL1 ENSG00000070371 ENSE00000596272 ENSE00001343357 Clathrin heavy chain 2
COL14A1 ENSG00000187955 ENSE00001022732 ENSE00001090753 Collagen alpha-1
COL14A1 ENSG00000187955 ENSE00000702894 ENSE00001476378 Collagen alpha-1
COPB1 ENSG00000129083 ENSE00000886038 ENSE00000703797 Coatomer subunit beta
COPB2 ENSG00000184432 ENSE00001322263 ENSE00001311447 Coatomer subunit beta
CP ENSG00000047457 ENSE00001008190 ENSE00000779559 Ceruloplasmin precursor
CSE1L ENSG00000124207 ENSE00000845497 ENSE00000845507 Exportin-2
CYFIP1 ENSG00000068793 ENSE00000883355 ENSE00000883353 Cytoplasmic FMR1-interacting protein
1
DCTN1 ENSG00000204843 ENSE00001261315 ENSE00001199793 Dynactin-1
ENO1 ENSG00000074800 ENSE00000739712 ENSE00000738913 Alpha-enolase
FAM62A ENSG00000139641 ENSE00000939452 ENSE00000939471 Protein FAM62A
FH ENSG00000091483 ENSE00000961691 ENSE00001069123 Fumarate hydratase, mitochondrial
precursor
FLII ENSG00000177731 ENSE00001289389 ENSE00001289270 Protein flightless-1 homolog.
FLNA ENSG00000196924 ENSE00000678331 ENSE00000868362 Filamin-A
GLUD1 ENSG00000148672 ENSE00000986500 ENSE00000986506 Glutamate dehydrogenase 1,
mitochondrial precursor
GPD2 ENSG00000115159 ENSE00000924640 ENSE00001188495 Glycerol-3-phosphate dehydrogenase,
mitochondrial precursor
GUCY1A3 ENSG00000164116 ENSE00001231799 ENSE00001081588 Guanylate cyclase soluble subunit
alpha-3
HD ENSG00000197386 ENSE00000854949 ENSE00000854981 Huntington disease protein
HD ENSG00000197386 ENSE00000854965 ENSE00001251513 Huntington disease protein
HD ENSG00000197386 ENSE00000854958 ENSE00000854991 Huntington disease protein
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HD ENSG00000197386 ENSE00000854979 ENSE00000855002 Huntington disease protein
HERC2 ENSG00000128731 ENSE00000672196 ENSE00001275912 Probable E3 ubiquitin-protein ligase
HERC2
HERC2 ENSG00000128731 ENSE00000672179 ENSE00001275876 Probable E3 ubiquitin-protein ligase
HERC2
HERC2 ENSG00000128731 ENSE00000908550 ENSE00000908562 Probable E3 ubiquitin-protein ligase
HERC2
HK1 ENSG00000156515 ENSE00001145338 ENSE00001276961 Hexokinase-1
HSD17B4 ENSG00000133835 ENSE00001143964 ENSE00000972282 Peroxisomal multifunctional enzyme
type 2
HSD17B4 ENSG00000133835 ENSE00001143927 ENSE00000972282 Peroxisomal multifunctional enzyme
type 2
HSD17B4 ENSG00000133835 ENSE00001169924 ENSE00001144014 Peroxisomal multifunctional enzyme
type 2
HSD17B4 ENSG00000133835 ENSE00001143964 ENSE00001143927 Peroxisomal multifunctional enzyme
type 2
HYOU1 ENSG00000149428 ENSE00001195270 ENSE00000990519 150 kDa oxygen-regulated protein
precursor
IQGAP2 ENSG00000145703 ENSE00000971759 ENSE00001030776 Ras GTPase-activating-like protein
IQGAP2.
ITGA2 ENSG00000164171 ENSE00001082079 ENSE00001082066 Integrin alpha-2 precursor
ITGA2 ENSG00000164171 ENSE00001082085 ENSE00001082079 Integrin alpha-2 precursor
ITGB3 ENSG00000056345 ENSE00000947489 ENSE00000735016 Integrin beta-3 precursor
ITIH2 ENSG00000151655 ENSE00001415117 ENSE00001395332 Inter-alpha-trypsin inhibitor heavy
chain H2 precursor
ITPR1 ENSG00000150995 ENSE00001072653 ENSE00001122088 Inositol 1,4,5-trisphosphate receptor
type 1
KIF5B ENSG00000170759 ENSE00001163763 ENSE00001163716 Kinesin heavy chain
KRT16 ENSG00000186832 ENSE00001118312 ENSE00001118295 Keratin, type I cytoskeletal 16
KTN1 ENSG00000126777 ENSE00001292736 ENSE00000867340 Kinectin
LCP2 ENSG00000043462 ENSE00000769281 ENSE00000812799 Lymphocyte cytosolic protein 2
LRRFIP2 ENSG00000093167 ENSE00000825531 ENSE00000760563 Leucine-rich repeat flightless-
interacting protein 2
LTBP1 ENSG00000049323 ENSE00000932484 ENSE00000932488 Latent-transforming growth factor
beta-binding protein, isoform 1L
precursor
LTBP1 ENSG00000049323 ENSE00000932483 ENSE00001006678 Latent-transforming growth factor
beta-binding protein, isoform 1L
precursor
LTBP1 ENSG00000049323 ENSE00000932485 ENSE00000744639 Latent-transforming growth factor
beta-binding protein, isoform 1L
precursor
LTBP1 ENSG00000049323 ENSE00000809557 ENSE00000744639 Latent-transforming growth factor
beta-binding protein, isoform 1L
precursor
MACF1 ENSG00000127603 ENSE00001041391 ENSE00001079474 Microtubule-actin cross-linking factor
1, isoforms 1/2/3/5
MACF1 ENSG00000127603 ENSE00001408360 ENSE00001218066 Microtubule-actin cross-linking factor
1, isoforms 1/2/3/5
MACF1 ENSG00000127603 ENSE00001411283 ENSE00001218029 Microtubule-actin cross-linking factor
1, isoforms 1/2/3/5
MACF1 ENSG00000127603 ENSE00001411283 ENSE00001041391 Microtubule-actin cross-linking factor
1, isoforms 1/2/3/5
MMRN1 ENSG00000138722 ENSE00001003940 ENSE00001003943 Multimerin-1 precursor
MTCH2 ENSG00000109919 ENSE00000714864 ENSE00001267224 Mitochondrial carrier homolog 2
MTHFD1 ENSG00000100714 ENSE00000658410 ENSE00000658424 C-1-tetrahydrofolate synthase,
cytoplasmic
Table 1. cont.
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MTHFD1 ENSG00000100714 ENSE00000658406 ENSE00000658420 C-1-tetrahydrofolate synthase,
cytoplasmic
MYH4 ENSG00000141048 ENSE00000907666 ENSE00000907657 Myosin-4
NID2 ENSG00000087303 ENSE00000854715 ENSE00000657316 Nidogen-2 precursor
NID2 ENSG00000087303 ENSE00000657316 ENSE00000854708 Nidogen-2 precursor
NPEPPS ENSG00000141279 ENSE00001138170 ENSE00001138132 Puromycin-sensitive aminopeptidase
NRBP1 ENSG00000115216 ENSE00000809167 ENSE00000733215 Nuclear receptor-binding protein.
OGDH ENSG00000105953 ENSE00000681534 ENSE00000681548 2-oxoglutarate dehydrogenase E1
component, mitochondrial precursor
PDIA5 ENSG00000065485 ENSE00001149277 ENSE00001353839 Protein disulfide-isomerase A5
precursor
PICALM ENSG00000073921 ENSE00000742961 ENSE00001376469 Phosphatidylinositol-binding clathrin
assembly protein
PIP5K2A ENSG00000150867 ENSE00000996551 ENSE00000996552 Phosphatidylinositol-4-phosphate 5-
kinase type-2 alpha
PKHD1L1 ENSG00000205038 ENSE00001477427 ENSE00001477413 fibrocystin L
PKHD1L1 ENSG00000205038 ENSE00001477417 ENSE00001477394 fibrocystin L
PKHD1L1 ENSG00000205038 ENSE00001477471 ENSE00001477421 fibrocystin L
PKHD1L1 ENSG00000205038 ENSE00001477455 ENSE00001477439 fibrocystin L
PKHD1L1 ENSG00000205038 ENSE00001477437 ENSE00001477347 fibrocystin L
PKHD1L1 ENSG00000205038 ENSE00001477474 ENSE00001477449 fibrocystin L
PLEC1 ENSG00000178209 ENSE00001244151 ENSE00001244041 Plectin-1
PLEC1 ENSG00000178209 ENSE00001244070 ENSE00001295392 Plectin-1
PLG ENSG00000122194 ENSE00000828808 ENSE00001315450 Plasminogen precursor
PLXDC2 ENSG00000120594 ENSE00001137970 ENSE00000996527 Plexin domain-containing protein 2
precursor
PROS1 ENSG00000184500 ENSE00001142430 ENSE00001142413 Vitamin K-dependent protein S
precursor.
PSMC6 ENSG00000100519 ENSE00000657442 ENSE00000657448 26S protease regulatory subunit S10B
PTPN18 ENSG00000072135 ENSE00000436095 ENSE00000776192 Tyrosine-protein phosphatase non-
receptor type 18
RAB8A ENSG00000167461 ENSE00001113277 ENSE00001277163 Ras-related protein Rab-8A
RASA3 ENSG00000185989 ENSE00001334941 ENSE00001334928 Ras GTPase-activating protein 3
RTN2 ENSG00000125744 ENSE00000858227 ENSE00000858223 Reticulon-2
SNX17 ENSG00000115234 ENSE00000734775 ENSE00000734780 Sorting nexin-17
SNX17 ENSG00000115234 ENSE00000962998 ENSE00000734785 Sorting nexin-17
SPTBN1 ENSG00000115306 ENSE00001036038 ENSE00001036017 Spectrin beta chain, brain 1
SRC ENSG00000197122 ENSE00001390472 ENSE00000661882 Proto-oncogene tyrosine-protein
kinase Src
STOM ENSG00000148175 ENSE00000983575 ENSE00001262522 Erythrocyte band 7 integral
membrane protein
THBS1 ENSG00000137801 ENSE00000883758 ENSE00000883772 Thrombospondin-1 precursor
TMEM33 ENSG00000109133 ENSE00001489658 ENSE00000712706 Transmembrane protein 33
TMOD3 ENSG00000138594 ENSE00001170748 ENSE00001102815 Tropomodulin-3
TPD52L2 ENSG00000101150 ENSE00000663594 ENSE00001391722 Tumor protein D54
UBASH3B ENSG00000154127 ENSE00001014167 ENSE00001014158 Suppressor of T-cell receptor signaling
1
UBE1L ENSG00000182179 ENSE00001305417 ENSE00001306981 Ubiquitin-activating enzyme E1
homolog
UGCGL1 ENSG00000136731 ENSE00001148961 ENSE00001206051 UDP-glucose:glycoprotein
glucosyltransferase 1 precursor
UGP2 ENSG00000169764 ENSE00001189522 ENSE00001165982 UTP–glucose-1-phosphate
uridylyltransferase 2
UNC13D ENSG00000092929 ENSE00001227797 ENSE00001406672 Unc-13 homolog D
Table 1. cont.
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We confirmed the presence of several mRNA species encoding
previously undescribed exon skip events by RT-PCR and
sequencing of the products. We chose 3 junctions identified in
the SkipE data for which evidence of protein expression was
obtained in the IPI search (Fig. 4). The proteins chosen were
integrin alpha 2 or platelet glycoprotein Ia (ITGA2), fumarate
hydratase (FH) and puromycin-sensitive aminopeptidase
(NPEPPS). These proteins represent different compartments and
perform various roles in the cell.
ITGA2 forms part of a platelet collagen receptor, involved in the
initial adhesion of platelets to extracellular matrix exposed at sites of
endothelial injury, such as atherosclerotic lesions [28,29]. Splice
variants may be functionally significant: a platelet-specific splice
variant may allow some tissue specific functions, while polymorphic
variations in ITGA2 are associated with risk of thrombotic stroke
[30]. The junction peptide we identified, which was formed by
splicing exon 26 to exon 29, occurred 3 times in the SkipE data and
16peptideswerepresentforthisprotein inthe IPI data. Thissplicing
event results in the deletion of 68 amino acids proximal to the single
transmembrane domain on the extracellular surface, far from any
reported ligand-binding domains. Similar changes in the length of
the ‘stalk’ of the platelet adhesion receptor GPIb are reported to
affect the ability of platelets to adhere at high flow rates [31].
FH is a Krebs’ cycle enzyme which is located in the cytosol or
can be transported to the mitochondrion and has been shown to
act as a tumor suppressor [32]. The FH junction under study was
formed by splicing exon 2 to exon 6 and was identified 5 times
with 7 different peptides identified in the IPI data.
The final protein selected, NPEPPS, is a puromycin-sensitive
aminopeptidase, common in brain and immune tissues. NPEPPS
may play a role in cell development and cell cycle-regulating
proteolysis [33]. The NPEPPS junction identified was created via
the splicing of exon 10 to exon 17 and occurred 4 times while 4
peptides were identified in IPI sequences.
The NPEPPS event was the longest skip we investigated,
removing 6 exons. Interestingly, skips of up to 96 exons were
observed – the distribution of skip lengths shown in Fig. 5 is highly
reminiscent of that observed by Sultan et al. in mRNAseq data
[14]. Such long skips remain to be verified (perhaps by the use of
2-dimensional gel separation followed by Western blotting and/or
MS), as the number of other potential AS events in genes
exhibiting long range AS gives rise to multiple PCR products (data
not shown). Primer pairs specific to the exons involved in each
junction generated multiple or ambiguous products with a
predominant band migrating at the ‘‘canonical’’ amplicon length.
It is likely that the AS message is present in relatively small
amounts and is out-competed by the canonical isoform in PCR.
Gene Symbol Ensembl Gene ID Exon ID 1 Exon ID 2 Description
UNC13D ENSG00000092929 ENSE00001227615 ENSE00001430590 Unc-13 homolog D
USP14 ENSG00000101557 ENSE00001208659 ENSE00001252715 Ubiquitin carboxyl-terminal hydrolase
14
VPS13A ENSG00000197969 ENSE00001024130 ENSE00000803886 Vacuolar protein sorting-associated
protein 13A
VPS13A ENSG00000197969 ENSE00001024085 ENSE00000708339 Vacuolar protein sorting-associated
protein 13A
VPS13A ENSG00000197969 ENSE00000708190 ENSE00000708458 Vacuolar protein sorting-associated
protein 13A
VPS13A ENSG00000197969 ENSE00001171911 ENSE00000803905 Vacuolar protein sorting-associated
protein 13A
VPS13A ENSG00000197969 ENSE00001024110 ENSE00000708298 Vacuolar protein sorting-associated
protein 13A
VPS13A ENSG00000197969 ENSE00001024141 ENSE00001024126 Vacuolar protein sorting-associated
protein 13A
VPS13A ENSG00000197969 ENSE00001024130 ENSE00000707929 Vacuolar protein sorting-associated
protein 13A
VPS13C ENSG00000129003 ENSE00001124918 ENSE00000885044 Vacuolar protein sorting-associated
protein 13C.
VPS13C ENSG00000129003 ENSE00001124912 ENSE00001364815 Vacuolar protein sorting-associated
protein 13C.
VPS13C ENSG00000129003 ENSE00000449795 ENSE00001380396 Vacuolar protein sorting-associated
protein 13C.
VPS13C ENSG00000129003 ENSE00000885045 ENSE00001368990 Vacuolar protein sorting-associated
protein 13C.
VPS13C ENSG00000129003 ENSE00000885061 ENSE00001484949 Vacuolar protein sorting-associated
protein 13C.
VPS13C ENSG00000129003 ENSE00000885061 ENSE00000885051 Vacuolar protein sorting-associated
protein 13C.
WAS ENSG00000015285 ENSE00000669947 ENSE00001255082 Wiskott-Aldrich syndrome protein
WDR44 ENSG00000131725 ENSE00000899838 ENSE00000899846 WD repeat protein 44
The Gene symbol, Ensembl gene and exon identifiers and the gene descriptions are listed for all 129 junctions found in 89 genes. The exon identifiers one and two
indicate the exons involved in the junction peptide identified in SkipE.
doi:10.1371/journal.pone.0005001.t001
Table 1. cont.
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PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e5001Figure 4. Exon skip events verified at mRNA level. Each numbered box represents an exon and the position in the gene. The skip event is
indicated by the diagonal lines. The parallelograms enclose the portion of amino acid sequence that is absent from the novel splice isoform. The bold
and underlined form the junction peptides.
doi:10.1371/journal.pone.0005001.g004
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paired them with compatible reverse primers providing a skip-
specific PCR primer pair (Table 2).
PCR products of the expected sizes were observed in each case
with cDNA derived both from platelets and from their precursors,
megakaryocytes. The bands derived from platelet cDNA were
excised and the sequence verified that the predicted products were
obtained. It can be seen from Figure 6 that the megakaryocyte
template produced a greater quantity of the amplicon in each case,
reflective of the availability of template rather than an increased
proportion of AS message in these cells.
Discussion
Our findings demonstrate that many exon skip events, which
have not been previously described, occur in platelets. These
events have been found in a novel high-throughput fashion. The
approach described is compatible with existing MS/MS software
solutions accessible to the scientific community. We have shown
that, while these events were found computationally, using a
proteomics platform, we selected and verified three of them at the
transcriptomic level by PCR and sequencing.
It is notable that the overlap of proteins, identified in the AS and
IPI databases, is relatively low – just 89 genes were represented by
peptides in both datasets. In common with many other high-
throughput experimental approaches such as yeast two-hybrid and
protein interaction networking [34,35], MS/MS proteomics
experiments suffer from a lack of completeness - that is, coverage
of the proteome is neither absolute nor unbiased. The completeness
of proteomics experiments is increased by high-throughput
approaches although approximately 10 repetitions of a multidi-
mensional protein identification technology (MudPIT) experiment
are required to reach 95% analytical completeness [36,37]. The
proteins identified in any given experiment will be constrained by a
number of factors including expression level and presence of
proteotypic peptides [38]. In the case of splice isoforms, these will
not necessarily correspond to the ‘canonical’ isoforms. Therefore,
although, in this experiment we used IPI-based detection of protein
expression to filter potential targets for verification, it is clear that
not all genes displaying AS will also be detected as canonical
isoforms and vice versa. Although we applied a relatively strict cutoff
of 0.9 to the SkipE hits, given the fact that they are subject to only
PeptideProphet and not ProteinProphet validation, it is possible
there are more false positives in the SkipE data than the IPI results.
Figure 5. Frequency distribution of exon skip lengths identified in the SkipE database. The number of occurrences of each skip length
identified is shown.
doi:10.1371/journal.pone.0005001.g005
Table 2. Design of exon-junction-spanning PCR primers.
Gene Junction Peptide Junction Primer Product Length (bp)
NPEPPS AQELDALDNSHPIEAR T CCT ATT GAA – GCT CGA GCT G 200
PI E A R
FH MPEFSGYVQQVK AA CGC ATG CCA – GAA TTT AGT G 165
MPEF S
ITGA2 ELIPLMIMKPDEK CC AAA GAA TTG – ATT CCC CTG A 115
EL IP L
The gene symbol, junction peptide sequence, junction primer and product length are shown. The junction primer column indicates, with a dash, the exon-exon
boundary.
doi:10.1371/journal.pone.0005001.t002
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skipevents detected in proteomics data will demonstrate the synergy
derived from the combination of high-throughput techniques and
these datasets will provide mutual cross validation.
It appears that the novel splice events detected in this study were
most likely inherited from the precursor rather than being specific
to the platelet. It will be interesting to determine the distribution of
these events in a variety of cell types and tissues across different
organisms. It will also be of interest to determine whether any of
the exon skip events occur specifically in the platelet since it is
known that splicing can occur in these cells, despite the absence of
a nucleus. While exon skips are the most common type of AS event
described to date [13,14,39,40], several other splicing patterns
occur during transcription including alternative 59 and 39 splice
sites and intron retention. These events require a different
approach to detection in proteomics data. Clearly, intron-specific
peptides could be incorporated into the SkipE database, though
this would considerably increase the database size. A parallel
intron peptide database would be a feasible approach. Alternative
59 or 39 splice sites on the other hand are not amenable to
detection in this manner and require an alternative approach.
In conclusion, we have developed a novel database, suitable for
the detection of alternative splicing in mass spectrometry data and
shown that it can detect AS events in a platelet MS/MS dataset.
The approach described augments current methodologies. Detec-
tion of AS directly at the protein level avoids any requirement for
amplification steps and indicates that the events detected are indeed
expressed. Millions of spectra, which are already available in both
public and private repositories, can be reanalyzed using this
database. As label-free quantitation tools are incorporated into
proteomics pipelines, the added value becomes even greater as
isoforms can be compared at the expression level within and
between samples. Again, this approach is applicable to the vast
repositories of data already gathered as well as to all new samples.
Theapplicationofthismethodologywillrapidlygive usnewinsights
into AS throughout a range of tissue types and biological states.
Since AS events have previously been associated with particular
diseases, the approach described here will allow the discovery of
disease-specific biomarkers at the splice isoform level. As the
proteome is the network most closely related to the biological
phenotype, the potential to discover clinically relevant biomarkers
related to diagnosis, prognosis or susceptibility is immense,
impacting on all levels of clinical practice and drug development.
Note added in proof
During the review process a similar database development was
described by Mo et al. [41].
Materials and Methods
Platelet MS/MS data acquisition
Platelets were prepared as previously described in McRedmond et
al. [42] and incubated at 37uC with stirring. One sample was
activated by the addition of 5 mM thrombin receptor activating
peptide for 5 minutes. Resting and activated samples were separated
into subcellular compartments using a ProteoExtract subcellular
proteome extraction kit (Merck Biosciences, Nottingham, UK). The
manufacturer’s protocol was modified to ensure separation of platelet
pellets from supernatants and to allow the recovery of released
platelet proteins. This procedure yields a ‘nuclear’ fraction, which is
artefactual when applied to platelets. Fractions from resting and
thrombin receptor activating peptide-activated platelets were sepa-
rated by SDS-PAGE; gel lanes were cut into 32 slices and digested
with trypsin. Peptides were separated by single-dimension reverse-
phase liquid chromatography and analysed using an LTQ ion trap
mass spectrometer (Thermo-Finnigan, San Jose, CA) [43].
Public data repositories
Ensembl version 46 was used to obtain all protein coding genes
and sequences, along with their associated exon predictions for the
human, mouse and rat genomes. Previously annotated AS events
in our dataset were filtered out by comparing sequences with
ASTD version 1.1 and IPI version 3.16 using Washington
University basic local alignment search tool (WU-BLAST) version
2.0, applying the pam30 substitution matrix.
Database development
Transcript and exon data were extracted, via the Perl-API, from
Ensembl v46 for all annotated genes in each of the human, mouse
and rat genomes. For each species, a separate database was
generated. Briefly, a standard ‘‘full-length transcript’’ containing,
for each exon position along the transcript, the longest predicted
exon sequence was generated. This procedure yields a single,
representative, ‘‘standard’’ transcript from which to design
junction peptides. The junction peptides are the derived peptide
sequences that span exon-exon junctions from the most C-terminal
protease site in the upstream exon to the most N-terminal protease
site in the downstream exon. In this case, we used trypsin as the
protease. Only the junctions of non-consecutive exons were
included in the database and the content was further constrained
by only including junctions in which phase was maintained
between exons. The fasta files for all three species are publicly
available online at http://bioinformatics.ucd.ie/SkipE.
Figure 6. Agarose gel electrophoresis of PCR products. Lanes 1–
5 show products amplified from megakaryocyte cDNA; samples in lanes
6–10 contained template from platelets. Molecular size markers are in
lane 11.
doi:10.1371/journal.pone.0005001.g006
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All MS/MS data analyses were carried out using the Proline
proteomics platform (Biontrack, Dublin http://www.biontrack.
com). Spectra were compared against databases using SEQUEST
[20]. Validation of peptides and proteins was carried out using the
transproteomics pipeline tools PeptideProphet and ProteinProphet
[21], respectively, and filtered with a cut-off of P.0.9.
RNA isolation
RNA from platelet and the megakaryocytic cell line Meg-01 was
isolated as previously described [42] and reverse-transcribed into
cDNA using standard techniques.
Validation
PCR and sequencing was carried out to validate the alternative
splicing events. All primer synthesis and sequencing was carried
out by MWG biotech (http://www.eurofinsdna.com/). Primer
sequences for ITGA2 were, forward CAAAGAATTGATT-
CCCCTGA and reverse TGCAACCAGAGCTAACAGCA.
NPEPPS forward primer is TCCTATTGAAGCTCGAGCTG
and reverse CAGCCCAGTCTCTCCCCTAT and FH forward
primer is AACGCATGCCAGAATTTAGTG and reverse is
CCACTTTTGCAGCAACCTTT. The PCR reactions were
made up as follows; 8 ml5 6GoTaq buffer, 1 ml Taq polymerase,
2 ml 4 mM dNTPs (Promega), 22 ml H2O, 2 ml primers and 1.5 ml
template. The following PCR conditions were used: 2 minutes of
denaturation at 94uC followed by 40 cycles of 30 seconds
denaturing at 94uC, 30 seconds annealing at 55uC for NPEPPS
and 58uC for FH and ITGA2 and a 90 second extension at 72uC
followed by incubation at 4uC. Products were separated on 2%
agarose gels. Positive control was integrin ITGA2B( a2B), a known
abundant platelet glycoprotein. Negative control was a no-
template RT reaction.
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